MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of hematology and oncology Ročník 14; číslo 1; s. 1 - 12
Hlavní autori:	Han, Jing, Liu, Yang, Yang, Sen, Wu, Xuan, Li, Hongle, Wang, Qiming
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 05.01.2021 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Amino acids Antimitotic agents Antineoplastic agents Apoptosis Binding sites Cancer Cancer Research Cancer therapies Cell differentiation Cell proliferation Chemotherapy Diarrhea Drug resistance Drug therapy Epidermal growth factor Extracellular signal-regulated kinase FDA approval Gene mutations Genetic aspects Health aspects Hematology Hypertension Immune checkpoint inhibitors Immunosuppressive agents Kinases Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell MAP kinase Medical prognosis Medical research Medicine Medicine & Public Health Medicine, Experimental MEK MEK inhibitors Metastasis Mutation Neutropenia Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Protein-tyrosine kinase Proteins RAF Raf protein RAS Review Schedules Signal transduction Small cell lung carcinoma Targeted therapy Tumor cells Tyrosine Vomiting MEK Targeted therapy RAS MEK inhibitors RAF ERK signaling pathway Non-small cell lung cancer
ISSN:	1756-8722, 1756-8722
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!